Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas
Science Translational Medicine · 2023
DOI: 10.1126/scitranslmed.ade8732 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Translational Medicine, 2023. Verfasst von Nobuhiko Kanaya und 15 weiteren Autor:innen. Beteiligte Einrichtung: Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA. Hauptthemen laut MEDLINE: Melanoma, Oncolytic Virotherapy, Oncolytic Viruses, Brain Neoplasms. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS.
Abstract (Originalsprache)
Oncolytic virus therapy has shown activity against primary melanomas; however, its efficacy in brain metastases remains challenging, mainly because of the delivery and immunosuppressive nature of tumors in the brain. To address this challenge, we first established PTEN-deficient melanoma brain metastasis mouse models and characterized them to be more immunosuppressive compared with primary melanoma, mimicking the clinical settings. Next, we developed an allogeneic twin stem cell (TSC) system composed of two tumor-targeting stem cell (SC) populations. One SC was loaded with oncolytic herpes simplex virus (oHSV), and the other SC was CRISPR-Cas9 gene-edited to knock out nectin 1 (N1) receptor (N1 KO ) to acquire resistance to oHSV and release immunomodulators, such as granulocyte-macrophage colony-stimulating factor (GM-CSF). Using mouse models of brain metastatic BRAF V600E /PTEN −/− and BRAF V600E/wt /PTEN −/− mutant melanomas, we show that locoregional delivery of TSCs releasing oHSV and GM-CSF (TSC-G) activated dendritic cell– and T cell–mediated immune responses. In addition, our strategy exhibited greater therapeutic efficacy when compared with the existing oncolytic viral therapeutic approaches. Moreover, the TSCs composed of SC-oHSV and SC N1KO –releasing GM-CSF and single-chain variable fragment anti–PD-1 (TSC-G/P) had therapeutic efficacy in both syngeneic and patient-derived humanized mouse models of leptomeningeal metastasis. Our findings provide a promising allogeneic SC-based immunotherapeutic strategy against melanomas in the CNS and a road map toward clinical translation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Gastroenterological Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama 700-8558, Japan.
- Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Neurosurgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Harvard Stem Cell Institute, Harvard University, Cambridge, MA 02138, USA.
ORCID-Profile: Nobuhiko Kanaya, Yohei Kitamura, Maria Lopez Vazquez, Arnaldo Franco, Kok-Siong Chen, Thijs A van Schaik, Waleed Seddiq, Shinji Kuroda, Genevieve Boland, David Fisher, Hiroaki Wakimoto, Khalid Shah
Förderung
- NCI NIH HHS
Zitieren
APA
Kanaya, N., Kitamura, Y., Lopez Vazquez, M., Franco, A., Chen, K. S., van Schaik, T. A., Farzani, T. A., Borges, P., Ichinose, T., Seddiq, W., Kuroda, S., Boland, G., Jahan, N., Fisher, D., Wakimoto, H., & Shah, K. (2023). Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas. Science Translational Medicine. https://doi.org/10.1126/scitranslmed.ade8732
Vancouver
Kanaya N, Kitamura Y, Lopez Vazquez M, Franco A, Chen KS, van Schaik TA, et al. Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas. Science Translational Medicine. 2023. doi:10.1126/scitranslmed.ade8732
BibTeX
@article{Kanaya2023,
author = {Kanaya, Nobuhiko and Kitamura, Yohei and Lopez Vazquez, Maria and Franco, Arnaldo and Chen, Kok-Siong and van Schaik, Thijs A and Farzani, Touraj Aligholipour and Borges, Paulo and Ichinose, Toru and Seddiq, Waleed and Kuroda, Shinji and Boland, Genevieve and Jahan, Nusrat and Fisher, David and Wakimoto, Hiroaki and Shah, Khalid},
title = {Gene-edited and -engineered stem cell platform drives immunotherapy for brain metastatic melanomas},
journal = {Science Translational Medicine},
year = {2023},
doi = {10.1126/scitranslmed.ade8732}
}
EUVIMED